SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorJingdong Zhang
About this trial
To investigate the efficacy of SHR-1701 combined with Rivoceranib, with or without SHR-2554, in patients with gastric or gastroesophageal junction adenocarcinoma who have progressed on or were intolerant to first-line immunotherapy-containing treatment
Eligibility criteria
Qualifiers
Age ≥ 18 years, male or female.
Histologically or pathologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma.
Disease progression on or intolerance to a prior treatment regimen that contained an immune checkpoint inhibitor (ICI).
HER2-negative expression.
Disqualifiers
Gastrointestinal perforation and/or fistula within 6 months prior to treatment, or active gastrointestinal bleeding within 3 months.
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
Known history of allergy to any component of the investigational drugs or their excipients.
Treatment with any other investigational agent within 4 weeks prior to the first dose of the study drug, or within 5 half-lives of the previous investigational agent (whichever is longer).
Trial design
Treatments tested in this trial
- SHR-1701+Rivoceranib + SHR-2554
- SHR-1701 + Rivoceranib
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Jingdong Zhang
Lead sponsor
China Medical University, China
Sponsor institution
Source ClinicalTrials.gov